A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock. AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...